CoronaVac can induce the production of anti-SARS-CoV-2 IgA antibodies in human milk

Calil, Valdenise Martins Laurindo Tuma; Palmeira, Patrícia; Zheng, Yingying; Krebs, Vera Lúcia Jornada; Carvalho, Werther Brunow de; Carneiro‐Sampaio, Magda

doi:10.6061/clinics/2021/e3185

Cited by 26 publications

(30 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, one study that evaluated the immunogenicity of mRNA vaccines also revealed the presence of binding and neutralizing antibodies in breast milk ( 60 ). One study including lactating women vaccinated with the inactivated virus COVID-19 vaccine found detectable anti-SARS-CoV-2 IgA antibodies in the breast milk ( 85 ). These data could indicate that breastfeeding in infancy has the potential to add to the protection conferred to infants via antibodies transferred across the placenta.…”

Section: Immunization During Pregnancymentioning

confidence: 99%

Global Perspectives on Immunization Against SARS-CoV-2 During Pregnancy and Priorities for Future Research: An International Consensus Paper From the World Association of Infectious Diseases and Immunological Disorders

et al. 2021

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pregnancy is associated with a higher risk for severe morbidity and mortality when compared with infection in non-pregnant women of childbearing age. An increasing number of countries recommend immunization against SARS-CoV-2 in pregnant women. Recent studies provide preliminary and supportive evidence on safety, immunogenicity and effectiveness of coronavirus disease 2019 (COVID-19) vaccines in pregnant women; however, important knowledge gaps remain which warrant further studies. This collaborative consensus paper provides a review of the current literature on COVID-19 vaccines in pregnant women, identifies knowledge gaps and outlines priorities for future research to optimize protection against SARS-CoV-2 in the pregnant women and their infants.

show abstract

Section: Immunization During Pregnancymentioning

confidence: 99%

Global Perspectives on Immunization Against SARS-CoV-2 During Pregnancy and Priorities for Future Research: An International Consensus Paper From the World Association of Infectious Diseases and Immunological Disorders

et al. 2021

View full text Add to dashboard Cite

show abstract

“…At present, a variety of COVID-19 vaccines have been successfully developed. In the current researches, the vaccines inoculated by lactating mothers are mainly BNT162B2 ( 18 , 19 ), mRNA-1273 ( 19 ), ChAdOx1-S ( 20 ), and CoronaVac ( 21 ), and there is no adverse reaction in infants has been caused by these vaccines through breastmilk ( 99 ).…”

Section: Specific Antibodies To Sars-cov-2 In Human Milkmentioning

confidence: 99%

“…The specific antibodies against SARS-CoV-2 have been proved in breastmilk from infected or vaccinated [BNT162b2 ( 18 , 19 ), mRNA-1273 ( 19 ), ChAdOx1-S ( 20 ), CoronaVac ( 21 )] mothers ( 22 , 23 ). Interestingly, specific antibodies are also found in neonatal umbilical cord blood and saliva of breastfed infants ( 11 , 24 , 25 ), proving the antibodies could be transferred to and protect the infants without significant adverse effects, which could explain the resistance of some neonates to SARS-CoV-2 ( 12 ).…”

Section: Introductionmentioning

confidence: 99%

Overview of Breastfeeding Under COVID-19 Pandemic

Pang

Tian

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

During the global pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), pregnant and lactating women are at higher risk of infection. The potential of viral intrauterine transmission and vertical transmission by breastfeeding has raised wide concerns. Breastmilk is rich in nutrients that contribute to infant growth and development, and reduce the incidence rate of infant illness and death, as well as inhibit pathogens significantly, and protect infants from infection. Although it is controversial whether mothers infected with COVID-19 should continue to breastfeed, many countries and international organizations have provided recommendations and guidance for breastfeeding. This review presents the risks and benefits of breastfeeding for mothers infected with COVID-19, and the reasons for the absence of SARS-CoV-2 active virus in human milk. In addition, the antiviral mechanisms of nutrients in breastmilk, the levels of SARS-CoV-2 specific antibodies in breastmilk from COVID-19 infected mothers and vaccinated mothers are also summarized and discussed, aiming to provide some support and recommendations for both lactating mothers and infants to better deal with the COVID-19 pandemic.

show abstract

“…Single-dose of CoronaVac to seropositive persons with a history of COVID-19 infection produced more antibodies than a double-dose of vaccine to seronegative individuals in Indonesia [ 169 ]. In an interesting development, Calil and coworkers claimed that CoronaVac can produce specific antibodies (IgA) against SARS-CoV-2 in human milk [ 170 ]. Reduced mortality rates have been reported among healthcare workers in Turkey after the introduction of the CoronaVac vaccine [ 171 , 172 ].…”

Section: Vaccines Approved For Public Usementioning

confidence: 99%

Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges

et al. 2021

View full text Add to dashboard Cite

The emergence of a novel coronavirus viz., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in late 2019 and its subsequent substantial spread produced the coronavirus disease 2019 (COVID-19) pandemic worldwide. Given its unprecedented infectivity and pathogenicity, the COVID-19 pandemic had a devastating impact on human health, and its clinical management has been a great challenge, which has led to the development and speedy trials of several vaccine candidates against SARS-CoV-2 at an exceptional pace. As a result, several COVID-19 vaccines were made commercially available in the first half of 2021. Although several COVID-19 vaccines showed promising results, crucial insights into their epidemiology, protective mechanisms, and the propensities of reinfection are not largely reviewed. In the present report, we provided insights into the prospects of vaccination against COVID-19 and assessed diverse vaccination strategies including DNA, mRNA, protein subunits, vector-based, live attenuated, and inactivated whole/viral particle-based vaccines. Next, we reviewed major aspects of various available vaccines approved by the World Health Organization and by the local administrations to use against COVID-19. Moreover, we comprehensively assessed the success of these approved vaccines and also their untoward effects, including the possibility of reinfection. We also provided an update on the vaccines that are under development and could be promising candidates in the future. Conclusively, we provided insights into the COVID-19 vaccine epidemiology, their potency, and propensity for SARS-CoV-2 reinfection, while a careful review of their current status, strategies, success, and future challenges was also presented.

show abstract

CoronaVac can induce the production of anti-SARS-CoV-2 IgA antibodies in human milk

Cited by 26 publications

References 8 publications

Global Perspectives on Immunization Against SARS-CoV-2 During Pregnancy and Priorities for Future Research: An International Consensus Paper From the World Association of Infectious Diseases and Immunological Disorders

Global Perspectives on Immunization Against SARS-CoV-2 During Pregnancy and Priorities for Future Research: An International Consensus Paper From the World Association of Infectious Diseases and Immunological Disorders

Overview of Breastfeeding Under COVID-19 Pandemic

Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges

Contact Info

Product

Resources

About